← Leaderboards
Chong-Xian Pan
University Of Calif-Lawrnc Lvrmr Nat Lab
$4,101,117
Attributed
$4,101,117
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $8.7M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,942,072 · 6
VA$0 · 4
By mechanism
U54$8,260,414 · 2
R01$1,782,912 · 1
K12$786,082 · 1
P41$112,664 · 2
I01$0 · 4
Top collaborators
- Luis Guillermo Carvajal Carmona5 shared
- Moon S Chen5 shared
Most similar at University Of Calif-Lawrnc Lvrmr Nat Lab
Same institution · by research overlap
- Sang Soo Hah$105,466
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoMalignant NeoplasmsMalignant Neoplasm Of Urinary BladderPharmaceutical PreparationsToxic EffectResponseTreatment OutcomeCellsClinical TrialsCancer CellSurfaceLigandsFundingNamesXenograft ProcedureDrug Delivery SystemsTargeted TreatmentFutureResistanceBladderResistance MechanismBaseCancer PatientCanis Familiaris
Grant awards (32)
A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer$0
I01 · FY2025 · VA · contact PI
BCCMA: Translational research to improve the care of advanced bladder cancer$0
I01 · FY2025 · VA · contact PI
A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer$0
I01 · FY2024 · VA · contact PI
BCCMA: Translational research to improve the care of advanced bladder cancer$0
I01 · FY2024 · VA · contact PI
A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer$0
I01 · FY2023 · VA · contact PI
BCCMA: Translational research to improve the care of advanced bladder cancer$0
I01 · FY2023 · VA · contact PI
Preclinical studies of KRAS and EGFR mutations in lung cancer PDXs$200,000
U54 · FY2022 · CA
A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer$0
I01 · FY2022 · VA · contact PI
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer$0
I01 · FY2021 · VA · contact PI
A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer$0
I01 · FY2021 · VA · contact PI
University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities$145,306
U54 · FY2020 · CA
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer$0
I01 · FY2020 · VA · contact PI
University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities$322,871
U54 · FY2019 · CA · contact PI
Targeted- and timed-releasing nanotherapeutics against leukemia stem cells$239,589
R01 · FY2019 · CA · contact PI
Targeted-and timed-releasing nanotherapeutics against leukemia stem cells$108,774
R01 · FY2019 · CA · contact PI
University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities$12,000
U54 · FY2019 · CA · contact PI
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer$0
I01 · FY2019 · VA · contact PI
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer$0
I01 · FY2019 · VA · contact PI
University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities$6,160,778
U54 · FY2018 · CA
Research Project 2$1,419,459
U54 · FY2018 · CA · contact PI
Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis$786,082
K12 · FY2018 · CA · contact PI
Targeted- and timed-releasing nanotherapeutics against leukemia stem cells$359,138
R01 · FY2018 · CA · contact PI
Potentiation of Immunotherapy with targeted nanoporphyrin in bladder cancer$0
I01 · FY2018 · VA · contact PI
Targeted- and timed-releasing nanotherapeutics against leukemia stem cells$359,138
R01 · FY2017 · CA · contact PI
Development of targeting nanotherapeutics against bladder cancer$0
I01 · FY2017 · VA · contact PI
Targeted- and timed-releasing nanotherapeutics against leukemia stem cells$358,851
R01 · FY2016 · CA · contact PI
Development of targeting nanotherapeutics against bladder cancer$0
I01 · FY2016 · VA · contact PI
Targeted- and timed-releasing nanotherapeutics against leukemia stem cells$357,422
R01 · FY2015 · CA · contact PI
Development of targeting nanotherapeutics against bladder cancer$0
I01 · FY2015 · VA · contact PI
Development of targeting nanotherapeutics against bladder cancer$0
I01 · FY2014 · VA · contact PI
DEVELOP ASSAY TO QUANT PLAT-DNA ADDUCTS & PREDICT RESPONSE TO CHEMOTHERA$58,316
P41 · FY2009 · RR · contact PI
DEVELOP ASSAY TO QUANT PLAT-DNA ADDUCTS & PREDICT RESPONSE TO CHEMOTHERA$54,348
P41 · FY2008 · RR · contact PI